Not exact matches
Teva said in a statement it would soon start producing a
generic version of the
drug that will be «
priced significantly
lower than Viagra,» which will result in «millions in savings to consumers» and «make this medication accessible to people who might otherwise not have been able to afford it.»
Plus, a handful of companies will typically all get approved to make a
generic at once, which ideally creates competition in the marketplace and can sometimes result in even
lower prices for those
drugs.
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may increase the amount of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability of funding for state AIDS
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction of generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and
price erosion caused by the introduction of
generic versions of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect of
lowering prices or reducing the number of insured patients; the possibility of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits of the Sangamo partnership; Gilead's ability to submit new
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the S
drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock
price, corporate or other market conditions; fluctuations in the foreign exchange rate of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
The whole industry faces turmoil with the advent of laws in several provinces demanding
lower prices on
generic drugs.
Profit declines sharply and company cuts full - year outlook
Cardinal Health Inc. reported a sharp decline in profit in its last quarter and lowered its full - year outlook following inventory write - downs in its overseas businesses and a sharper - than - anticipated decline in generic drug prices.
And the revised deal will let Rite Aid buy
generic drugs through a Walgreens affiliate, allowing the smaller chain access to the
lower prices enjoyed by its bigger competitor.
Once a
drug loses its patents,
generic drug manufacturers start selling copycat versions at substantially
lower prices.
WASHINGTON (AP)-- Some
low - cost
generic drugs that have helped restrain health care costs for decades are seeing unexpected
price spikes of up to 8,000 percent, prompting a backlash from patients, pharmacists and now Washington lawmakers.
In addition, researchers found
low market competition levels had a more pronounced correlation with
drug prices in
lower -
priced generic drugs compared with their higher -
priced counterparts.
The
drugs are now available as
lower -
priced generics, poised to further drive consumption.
After controlling for other factors, a
generic drug in the highest marketing competition group was expected to see a decrease of 32 percent in
price over the study period, while a
generic drug in the
lowest market competition was expected to see a
price increase of 47 percent over the same period.
As it has for its HIV
drugs, Gilead plans to provide patient assistance within the U.S., to license the
drug (for a fee) to select
generic manufacturers outside the U.S., and to
lower prices in
low - and middle - income countries.
The Patent Act and the PM (NOC) Regulations seek to balance «effective patent enforcement» over new and innovative
drugs with the «timely market entry» of
lower priced generic versions once the patents have expired.
Generally,
generic drugs on the
lowest priced tier, though this is not always the case — UnitedHealthcare makes a point to monitor the
prices of high cost
generics to make sure they're the best value.
In such patients,
low priced generic risk pills that combine aspirin with a statin
drug in order to reduce cholesterol and
lower blood pressure can bring down the chances of suffering another stroke or even dying by two - thirds.